Geode Capital Management
TLIS

Geode Capital Management’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Geode Capital Management’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,020
Closed -$123K – 4616
2024
Q2 		$123K Buy
14,020
+2,130
+18% +$18.9K ﹤0.01% 4076
2024
Q1 		$104K Buy
11,890
+610
+5% +$5.03K ﹤0.01% 4150
2023
Q4 		$84.1K Hold
11,280
– – ﹤0.01% 4234
2023
Q3 		$64.9K Buy
11,280
+1,911
+20% +$13.1K ﹤0.01% 4361
2023
Q2 		$67.5K Sell
9,369
-259
-3% -$1.88K ﹤0.01% 4441
2023
Q1 		$70.8K Hold
9,628
– – ﹤0.01% 4440
2022
Q4 		$64K Sell
9,628
-22
-0.2% -$193 ﹤0.01% 4527
2022
Q3 		$98K Hold
9,650
– – ﹤0.01% 4586
2022
Q2 		$117K Sell
9,650
-8,010
-45% -$127K ﹤0.01% 4526
2022
Q1 		$373K Sell
17,660
-1,111
-6% -$38.5K ﹤0.01% 4091
2021
Q4 		$1.13M Sell
18,771
-1,427
-7% -$107K ﹤0.01% 3656
2021
Q3 		$1.89M Buy
20,198
+2,995
+17% +$399K ﹤0.01% 3370
2021
Q2 		$2.85M Buy
17,203
+1,735
+11% +$295K ﹤0.01% 3159
2021
Q1 		$2.98M Buy
+15,468
New +$3.86M ﹤0.01% 3056

Other funds holding TLIS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Geode Capital Management's TLIS Position: Q3 2024 in Review

Geode Capital Management sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2024, closing a stake of 14,020 shares — an estimated $123K sold.

Geode Capital Management first reported a position in TLIS in Q1 2021 and held it in 14 quarters. The position peaked at $2.98M in Q1 2021. 2 funds tracked by Wall St. Rank hold TLIS as of Q3 2024.

  • Geode Capital Management reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2024 after selling out during the quarter.
  • Geode Capital Management sold 14,020 Talis Biomedical Corporation Common Stock shares in Q3 2024, an estimated $123K.
  • Geode Capital Management first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 14 quarters.
  • Geode Capital Management's Talis Biomedical Corporation Common Stock position peaked at $2.98M in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2024.

Based on Geode Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.